Change in proportion of patients on metformin, sulfonylureas, dipeptidyl peptidase-4 inhibitors (DPP4s), sodium-glucose cotransporter 2 inhibitors (SGLT2s), and glucagon-like peptide 1 receptor agonists (GLP1s) between 2012 and 2017
| Medication class | Nation | Change in proportion of patients on medication, % (95% CI) | |
|---|---|---|---|
| Metformin | |||
| Australia | 3.4 | (3.24 to 3.55) | |
| Canada | −4.7 | (−5.05 to −4.34) | |
| England | −1.4 | (−1.60 to −1.30) | |
| Scotland | −0.7 | (−1.16 to −0.29) | |
| Sulfonylurea | |||
| Australia | −8.8 | (−9.00 to −8.59) | |
| Canada | −7.6 | (−8.10 to −7.18) | |
| England | −9.9 | (−10.10 to −9.63) | |
| Scotland | 1.4 | (0.77 to 2.02) | |
| DPP4 | |||
| Australia | 12.6 | (12.41 to 12.79) | |
| Canada | 10.4 | (10.07 to 10.73) | |
| England | 11.1 | (10.96 to 11.34) | |
| Scotland | 10.2 | (9.68 to 10.71) | |
| SGLT2 | |||
| Australia | 15.3 | (15.17 to 15.43) | |
| Canada | 11.6 | (11.38 to 11.82) | |
| England | 10.1 | (9.94 to 10.16) | |
| Scotland | 10.1 | (9.75 to 10.45) | |
| GLP1 | |||
| Australia | 2.9 | (2.81 to 2.98) | |
| Canada | 1.4 | (1.30 to 1.50) | |
| England | 1.3 | (1.17 to 1.39) | |
| Scotland | 1.3 | (1.06 to 1.54) | |